Physician profile
Michael Lewitton
NPI 1558313692
$24,934.04
in general payments reported to CMS, 2019-2025
72 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,083 · 2020: $1,076 · 2021: $1,126 · 2022: $2,433 · 2023: $2,506 · 2024: $3,311 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,721 · Long Term Medical Supply Or Device Loan: $5,143 · Consulting Fee: $2,173 · Education: $161 · Entertainment: $18.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,720.78 |
| Long Term Medical Supply Or Device Loan | $5,142.85 |
| Consulting Fee | $2,172.50 |
| Education | $160.74 |
| Entertainment | $18.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hmu Consumables, LLC | $5,142.85 | 2025 | Dornier Medtech |
| Boston Scientific Corporation | $3,264.95 | 2019-2025 | Spaceoar Vue System - 10ml, Spaceoar System, Moses 550 Dfl |
| Ferring Pharmaceuticals INC. | $2,942.03 | 2019-2025 | Adstiladrin |
| Janssen Biotech, INC. | $1,439.79 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Astellas Pharma US INC | $1,130.01 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Abbvie INC. | $1,033.71 | 2019-2025 | |
| Pfizer INC. | $917.22 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $778.25 | 2020-2025 | Prolaris |
| Antares Pharma, INC. | $640.46 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $533.35 | 2023-2025 | Orgovyx, Gemtesa |
| Progenics Pharmaceuticals, INC. | $523.80 | 2021-2025 | Pylarify |
| Biotissue Holdings INC. | $393.85 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $364.05 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $352.98 | 2019-2023 | Xiaflex, Aveed, Edex |
| Olympus America INC. | $341.75 | 2019-2025 | Itind System |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $288.37 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $287.11 | 2025 | Tlando, Trelstar |
| Endo USA, INC. | $284.51 | 2024-2025 | Xiaflex, Aveed |
| Procept Biorobotics Corporation | $281.89 | 2022-2025 | Aquabeam System |
| Amgen INC. | $258.87 | 2019-2024 | Prolia |
| Dendreon Pharmaceuticals LLC | $250.44 | 2019-2025 | Provenge |
| Myovant Sciences INC. | $240.05 | 2021-2022 | |
| Convatec INC. | $237.92 | 2022-2023 | |
| Medtronic, INC. | $209.04 | 2024-2025 | Interstim |
| Axonics, INC. | $208.88 | 2020-2024 | Axonics |
| Accord Healthcare, INC. | $207.39 | 2023-2025 | |
| Neotract INC. | $181.58 | 2019 | |
| Ambu INC. | $123.64 | 2021-2024 | |
| Tolmar, INC. | $123.18 | 2023-2025 | Eligard, Jatenzo |
| Smith+Nephew, INC. | $115.98 | 2023 | Stravix Pl |
| Blue Earth Diagnostics | $110.56 | 2022-2025 | Posluma |
| Laborie Medical Technologies Corp. | $106.20 | 2022-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Terumo Medical Corporation | $103.23 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $96.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $89.31 | 2025 | |
| Urovant Sciences INC | $82.78 | 2021-2022 | |
| Urogen Pharma, INC. | $81.32 | 2022-2024 | Jelmyto |
| Merck Sharp & Dohme LLC | $80.75 | 2020-2023 | Keytruda |
| Baxter Healthcare | $61.09 | 2024 | Perclot |
| Teleflex LLC | $57.93 | 2023-2024 | Urolift |
| Checkpoint Surgical, INC | $56.90 | 2024 | Checkpoint Stimulators |
| Abc Home Medical Supply, INC. | $53.31 | 2022-2025 | |
| Acerus Pharmaceuticals Corporation | $53.08 | 2020-2022 | |
| Healthtronics Stone Solutions, LLC | $48.54 | 2024 | Dornier Medtech |
| Astrazeneca Pharmaceuticals LP | $48.34 | 2020-2022 | |
| Stryker Corporation | $48.17 | 2025 | 1788 |
| Halozyme INC | $41.61 | 2023 | |
| Immunitybio, INC. | $41.18 | 2024-2025 | |
| Avanos Medical | $37.84 | 2024 | On-Q* Pump and Accessories |
| Pacira Pharmaceuticals Incorporated | $37.38 | 2025 | Exparel |
| Travere Therapeutics, INC. | $35.53 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $32.48 | 2022 | |
| Azurity Pharmaceuticals, INC. | $29.35 | 2025 | Azmiro |
| Janssen Pharmaceuticals, INC | $28.68 | 2019 | |
| Genzyme Corporation | $27.09 | 2022 | |
| Sun Pharmaceutical Industries INC. | $26.59 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $26.12 | 2019 | |
| 180 Medical, INC. | $24.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.11 | 2025 | Oxlumo |
| Caris Mpi, INC. | $23.55 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $23.24 | 2024 | |
| Emd Serono, INC. | $23.12 | 2025 | |
| Cook Medical LLC | $21.21 | 2024 | Cook |
| Kerecis Limited | $19.53 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Rgh Enterprises LLC | $19.21 | 2019 | |
| Provepharm INC. | $18.94 | 2024 | Bludigo |
| Dentsply Ih INC. | $18.88 | 2020 | |
| Abbott Laboratories | $18.82 | 2019 | |
| Aytu Biopharma, INC. | $16.46 | 2019 | |
| Integra Lifesciences Corporation | $16.04 | 2025 | Cytal |
| Baudax Bio INC. | $14.46 | 2020 | |
| Renovia INC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,814.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lewitton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.